Ipamorelin vs Sermorelin: Research Compared

The short answer

Ipamorelin and sermorelin are both studied in relation to the growth hormone axis, but they belong to different compound classes and act on different receptors. Sermorelin is a growth hormone releasing hormone (GHRH) analogue that targets the GHRH receptor, while ipamorelin is a growth hormone secretagogue that acts as an agonist at the ghrelin receptor (GHS-R). This article compares the two by mechanism and research evidence stage only. It is not a recommendation to use either compound, and neither is framed here as superior or suitable for any personal purpose.

What is sermorelin (a GHRH analogue)

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human growth hormone releasing hormone, which is why it is also written as GHRH (1-29) or GRF (1-29). This fragment is generally described in the literature as the shortest sequence that retains the biological activity of the full GHRH molecule. It was characterised during research into the hypothalamic and pituitary regulation of the growth hormone axis in the late twentieth century.

Sermorelin has a notable regulatory history. It was previously marketed under the brand name Geref, with a diagnostic product approved in the United States in 1990 and a paediatric product approved in 1997. The manufacturer later notified regulators that both products were being discontinued, and the relevant approvals were withdrawn in 2009. As of 2026 there is no approved sermorelin product marketed under that brand. This history is relevant context when the compound is described, but it does not translate into any current approval.

How sermorelin is usually described

• A GHRH analogue based on the GRF (1-29) sequence
• A compound that was once an approved product (Geref) and was later discontinued
• Studied historically in relation to pituitary function and the growth hormone axis
• Not a currently approved medicine and not a wellness supplement

What is ipamorelin (a ghrelin receptor agonist)

Ipamorelin is a synthetic pentapeptide, meaning it is made up of five amino acids. It is classed as a growth hormone secretagogue and acts as an agonist at the ghrelin receptor, formally the growth hormone secretagogue receptor type 1a (GHS-R1a). In the research literature it is often described as relatively selective among the secretagogue class, a feature that made it of interest in early pharmacological characterisation.

Ipamorelin was investigated in clinical research but did not progress to approval. Reported work includes phase 2 investigation in the context of postoperative gut function, where development was discontinued after the studied endpoints were not met. As of 2026 ipamorelin is not an approved medicine in any major jurisdiction, and it has no marketing authorisation from bodies such as the TGA, FDA, EMA or MHRA.

How ipamorelin is usually described

• A pentapeptide growth hormone secretagogue
• An agonist at the ghrelin receptor (GHS-R1a)
• Often described as relatively selective within its class
• Investigated in trials but never approved as a medicine anywhere

The core mechanistic difference

The most important distinction between the two compounds is the receptor each one targets. The growth hormone axis is influenced by more than one signalling pathway, and these two peptides engage different ones.

Sermorelin mirrors GHRH and is studied as an agonist at the GHRH receptor on the pituitary. Ipamorelin instead engages the ghrelin receptor (GHS-R1a), a separate receptor that the endogenous hormone ghrelin acts on. Because they bind different receptors, the two compounds are grouped under the broad research umbrella of growth hormone secretagogues but sit in different sub-classes: GHRH analogues on one side and ghrelin receptor agonists, sometimes called ghrelin mimetics, on the other.

Sermorelin is a GHRH analogue acting at the GHRH receptor. Ipamorelin is a ghrelin receptor agonist acting at GHS-R1a. Same broad research category, different molecular target.

This mechanistic separation is the main reason the two are frequently discussed side by side in the literature. They are not interchangeable descriptions of the same thing, and understanding which receptor each targets is the starting point for any accurate comparison.

Research and evidence stage of each

Both compounds have been studied, but neither has a body of large, confirmatory human evidence behind the popular claims often attached to them online. Describing the evidence stage honestly means separating mechanistic characterisation from demonstrated outcomes.

Sermorelin carries the unusual position of having once been an approved product that was later discontinued, so its historical evaluation reached a regulatory stage that ipamorelin never did. Ipamorelin, by contrast, remained investigational and its reported clinical development was discontinued. For both compounds, much of what circulates about broader effects is extrapolated from mechanism rather than established by robust, peer-reviewed human trials.

Regulatory status in Australia

In Australia, the general picture for both compounds is the same at a high level. Neither ipamorelin nor sermorelin is an approved therapeutic good entered on the Australian Register of Therapeutic Goods (ARTG). Growth hormone secretagogues and GHRH analogues are not approved medicines for general supply, they are not wellness supplements, and they are not sold here for human therapeutic use.

Because the exact scheduling treatment of individual research peptides can be nuanced, this article does not assign a specific Poisons Standard schedule number to either compound. The accurate and conservative summary is that both are outside the approved-medicine framework in Australia and are handled as research chemicals rather than consumer products. Anyone needing a precise legal classification should consult the current TGA Poisons Standard or an appropriately qualified professional directly.

In the sporting context the position is clearer. Growth hormone secretagogues, including both GHRH analogues such as sermorelin and ghrelin mimetics such as ipamorelin, fall within category S2 of the World Anti-Doping Agency Prohibited List, which covers peptide hormones, growth factors and related substances. Substances in this category are prohibited at all times, and this applies to athletes under Sport Integrity Australia.

How they are classed for research supply

For supply within a research-use-only catalogue, both compounds are treated as reference materials rather than finished products intended for a person. The relevant descriptors are the compound class, the amino acid sequence or peptide length, and the receptor target, not any claimed benefit.

The accurate research descriptors

• Sermorelin: GHRH analogue, GRF (1-29) sequence, GHRH receptor target
• Ipamorelin: pentapeptide growth hormone secretagogue, GHS-R1a (ghrelin receptor) target
• Both: research use only, not for human or veterinary use, not ARTG listed
• Both: prohibited in sport under WADA category S2

Framing supply this way keeps the description tied to verifiable chemistry and regulatory facts. It avoids implying that either compound is approved, safe for any personal purpose, or interchangeable with a medicine.

How researchers frame the comparison

When the two appear together in the literature, the comparison is usually mechanistic. Researchers describe sermorelin as a tool for probing the GHRH receptor pathway and ipamorelin as a tool for probing the ghrelin receptor pathway. The interest lies in how two different receptor systems both feed into growth hormone physiology, not in ranking one compound above the other.

A second common framing is historical and regulatory. Sermorelin is the older, GHRH-based molecule that reached and then left the approved-product stage, while ipamorelin is a later secretagogue that stayed investigational. Noting these different trajectories is factual context, and it is distinct from any claim about effectiveness.

In short, a neutral comparison answers three questions: what class is each compound, which receptor does each target, and what is each compound's documented regulatory and research history. It does not answer which one someone should use, because that framing does not apply to a research-use-only compound.

Frequently asked questions